Breaking News

My opinion about opinion

March 2, 2025
avatar-torie-bosch
First Opinion editor
Get psyched: The first round of voting for STAT Madness launches Monday.

Recently, Jeff Bezos announced that the Washington Post opinion section will now promote a single viewpoint around "personal liberties and free markets." Opinion editor David Shipley will be leaving, and the Post is searching for his replacement.

After the news came out, some people, including STAT executive editor Rick Berke, asked me if I would have stayed if I were Shipley. I had to say no.

Opinion sections are strange beasts. Historically, they do align with the owner's politics — witness the Wall Street Journal, whose conservative opinion section is aligned with owner Rupert Murdoch's point of view. And I think that's fine, so long as that perspective is clearly stated and doesn't influence the reporting. In that sense, Bezos has the right to do what he wants.

But for a paper that has traditionally published a wide range of viewpoints to suddenly pull back is not the same having a baked-in perspective from the beginning.

I also think that at this political moment, we don't need more siloed opining. We need more clear, well-argued op-eds from a variety of authors, including those in disagreement. That's how readers can best understand the limits of their own thinking.

Plus: Only publishing the same points of view over and over again? How boring, as both a reader and editor.

What's your opinion about my opinion of opinion pages? Tell me about it.

Recommendation of the week: "Yellowjackets" is back for a third season on Showtime/Paramount Plus, and while it is somewhat diminished from its glorious first season, I can't stop watching. The '90s music, Melanie Lynskey, Christina Ricci, "there's no book club?!?" — who knew a show about cannibalism could be so comforting?



ARIS OIKONOMOU/AFP via Getty Images

How physician exhaustion kills compassion — and nurtures shame

"A patient's family chose comfort care, and my first thought was, 'One less.'": How lack of sleep shreds doctors' empathy.

By Laura B. Vater


To fight for those with rare diseases, Trump must reform and modernize the FDA thoughtfully

Trump has the power to advance a "virtuous circle" of innovation to help those with rare genetic diseases, cancer, Alzheimer's, and many other maladies.

By John F. Crowley


The Trump years will be grim for long Covid sufferers

The disbanding of an HHS advisory committee may signal the end of federal involvement in addressing long Covid.

By Steven Phillips


ANTOINE BOUREAU/Hans Lucas/AFP via Getty Images

STAT+ | What diagnostic tests can teach about spotting public fraud

To reduce waste and fraud in government programs, the administration must improve its detection accuracy by improving sensitivity and specificity.

By Lee Kennedy-Shaffer


STAT+ | There's a better way to get drugs on the market: progressive approval

Unlike the accelerated approval process, a progressive approach would benefit both companies and patients.

By Eric D. Perakslis and Michael Stebbins


RFK Jr.'s dangerous misuse of 'informed consent' on vaccines

STAT First Opinion: Giving people a list of possible vaccine side effects without context is not the kind of "informed consent" worth promoting.

By Mark C. Navin, Lainie Friedman Ross, and Jason A. Wasserman


OLIVIER DOULIERY/AFP via Getty Images

'Ultra-processed food' is too broad a term to be useful

Legislatures, governors, government agencies, and plaintiff attorneys are taking action against ultra-processed foods, but there is no clear definition.

By Chris Gismondi and Megan Kinney


What academic research could learn from college athletics

Federal rules have fenced off academic researchers from business-funded basic science — just as NCAA rules constrained athletes.

By Morris W. Foster


STAT+ | Why AI like Grok isn't ready for the radiology big leagues

After an X user claimed Grok correctly identified a human fracture, I wanted to test it out for myself. Here's what happened.

By Kalyan Sivasailam


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying First Opinion? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2025, All Rights Reserved.

No comments